MPM BioImpact LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001687078
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 38 positions · Total reported value $873.95M · Top-10 concentration 49.8% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 81.2% · 7 new · 21 cut · 11 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +31.4% · vs SPY +16.6% · Prev Value $1.29B — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2025 13F filing, MPM BioImpact LLC disclosed 38 equity positions with a combined reported value of $873.95M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 49.8% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were CGEM ($79.16M), MDGL ($56.36M), LQDA ($48.32M). By sector, the heaviest allocations are Health Care 96.8%, Other 3.2%. Versus the prior quarter, allocation shifted toward Health Care (+4.1pp) and away from Other (-4.1pp).
Versus the prior quarter, MPM BioImpact LLC opened 7 new positions, trimmed 21 and fully exited 11, a turnover rate of 81.2% of positions. The portfolio's overlap with the prior quarter was 42% of names.
The largest new positions opened in Q4 2025 were AGIO ($35.48M), QURE ($33.06M), ALMS ($23.44M).
Of the 11 positions fully exited versus the prior quarter, the largest were RNAM ($33.11M), ZLAB ($25.25M), CMPX ($17.77M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
- AGIO AGIOS PHARMACEUTICALS INC · $35.48M
- QURE UNIQURE NV · $33.06M
- ALMS ALUMIS INC · $23.44M
- CRVS CORVUS PHARMACEUTICALS I · $21.13M
- GLUE MONTE ROSA THERAPEUTICS INC · $18.40M
- DRUG BRIGHT MINDS BIOSCIENCES INC · $17.96M
- PTGX PROTAGONIST THERAPEUTICS INC · $17.42M
- ARQT ARCUTIS BIOTHERAPEUTICS INC · $15.43M
Fully Exited (vs previous quarter)
- RNAM AVIDITY BIOSCIENCES INC · prev qtr: $33.11M
- ZLAB Zai Lab Ltd · prev qtr: $25.25M
- CMPX COMPASS THERAPEUTICS INC · prev qtr: $17.77M
- ALKS ALKERMES PLC · prev qtr: $16.48M
- VERA VERA THERAPEUTICS INC · prev qtr: $16.36M
- JANX JANUX THERAPEUTICS INC · prev qtr: $15.01M
- SPRY ARS PHARMACEUTICALS INC · prev qtr: $13.10M
- RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $11.90M · history
Insider Transactions (Form 4)
Latest MPM BioImpact LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
MPM BioImpact LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 37 positions worth $1.64B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-106989 (status: Approved), registered 2016-01-04
- Regulatory AUM (Form ADV): $3.56B as of 2026-04-28
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 14 private funds, of which 3 hedge funds
Portfolio Structure
- 37 positions · $1.64B reported value (Q2 2026)
- Top 10 holdings = 55.3% of reported value
- Largest position: CGEM (CULLINAN THERAPEUTICS INC) at 10.8%
- Average position size: $44.32M
Sector Tilt
- Health Care 98.7%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 7 new, 7 added, 21 reduced, 11 exited
- 2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
7.65M | $79.16M | 9.06% | Hold | |
| 2 |
|
96.78K | $56.36M | 6.45% | Reduce | |
| 3 |
|
1.40M | $48.32M | 5.53% | Add | |
| 4 |
|
3.29M | $41.15M | 4.71% | Reduce | |
| 5 |
|
1.66M | $41.08M | 4.70% | Reduce | |
| 6 |
|
505.67K | $40.28M | 4.61% | Add | |
| 7 |
|
1.30M | $35.48M | 4.06% | New | |
| 8 |
|
1.38M | $33.06M | 3.78% | New | |
| 9 |
|
430.01K | $32.66M | 3.74% | Reduce | |
| 10 |
|
1.34M | $28.11M | 3.22% | Reduce | |
| 11 |
|
1.41M | $27.49M | 3.15% | Reduce | |
| 12 |
|
328.87K | $26.93M | 3.08% | Reduce | |
| 13 |
|
770.29K | $24.45M | 2.80% | Reduce | |
| 14 |
|
2.40M | $23.44M | 2.68% | New | |
| 15 |
|
941.38K | $22.05M | 2.52% | Add | |
| 16 |
|
485.62K | $21.77M | 2.49% | Reduce | |
| 17 |
|
205.75K | $21.54M | 2.46% | Add | |
| 18 |
|
93.55K | $21.43M | 2.45% | Reduce | |
| 19 |
|
2.74M | $21.13M | 2.42% | New | |
| 20 |
|
996.83K | $19.11M | 2.19% | Reduce | |
| 21 |
|
2.23M | $18.89M | 2.16% | Reduce | |
| 22 |
|
1.17M | $18.40M | 2.10% | New | |
| 23 |
|
230.15K | $17.96M | 2.06% | New | |
| 24 |
|
199.47K | $17.42M | 1.99% | New | |
| 25 |
|
1.84M | $16.62M | 1.90% | Add | |
| 26 |
|
10.68M | $15.70M | 1.80% | Reduce | |
| 27 |
|
531.20K | $15.43M | 1.76% | New | |
| 28 |
|
1.64M | $14.80M | 1.69% | New | |
| 29 |
|
1.80M | $14.71M | 1.68% | Add | |
| 30 |
|
87.76K | $14.04M | 1.61% | New | |
| 31 |
|
397.91K | $13.48M | 1.54% | New | |
| 32 |
|
2.67M | $10.69M | 1.22% | New | |
| 33 |
|
56.32K | $7.59M | 0.87% | New | |
| 34 |
|
1.59M | $5.57M | 0.64% | Reduce | |
| 35 |
|
81.14K | $3.36M | 0.39% | New | |
| 36 |
|
113.02K | $1.93M | 0.22% | New | |
| 37 |
|
70.00K | $1.51M | 0.17% | Reduce | |
| 38 |
|
1.39M | $883.51K | 0.10% | Reduce | |
FAQ
What did MPM BioImpact LLC buy in 2025-Q4?
In its 2025-Q4 13F filing, MPM BioImpact LLC reported 38 equity positions worth $873.95M in aggregate; its largest disclosed positions were CGEM ($79.16M), MDGL ($56.36M), LQDA ($48.32M).
How large is MPM BioImpact LLC's portfolio?
MPM BioImpact LLC reported $873.95M of long equity holdings across 38 positions as of 2025-Q4. Top-10 holdings account for 49.8% of reported value.
What is MPM BioImpact LLC's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.